Wealth Enhancement Advisory Services LLC acquired a new stake in Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 57,860 shares of the biopharmaceutical company’s stock, valued at approximately $2,114,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Janus Henderson Group PLC raised its position in shares of Pfizer by 243.5% during the second quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock worth $442,574,000 after acquiring an additional 9,339,749 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Pfizer by 2.3% during the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after acquiring an additional 9,239,499 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Pfizer during the second quarter worth $268,389,000. Stifel Financial Corp raised its position in shares of Pfizer by 5,413.5% during the third quarter. Stifel Financial Corp now owns 7,360,192 shares of the biopharmaceutical company’s stock worth $262,515,000 after acquiring an additional 7,226,697 shares during the last quarter. Finally, Longview Partners Guernsey LTD raised its position in shares of Pfizer by 32.0% during the third quarter. Longview Partners Guernsey LTD now owns 24,369,672 shares of the biopharmaceutical company’s stock worth $869,997,000 after acquiring an additional 5,901,100 shares during the last quarter. Hedge funds and other institutional investors own 71.16% of the company’s stock.

How to Become a New Pot Stock Millionaire

Pfizer stock opened at $36.27 on Thursday. Pfizer Inc. has a 52 week low of $31.67 and a 52 week high of $39.43. The company has a quick ratio of 1.10, a current ratio of 1.35 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $216,267.59, a PE ratio of 10.33, a price-to-earnings-growth ratio of 2.05 and a beta of 0.91.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.06. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The firm had revenue of $13.70 billion during the quarter, compared to analysts’ expectations of $13.67 billion. During the same period in the previous year, the firm earned $0.47 earnings per share. The company’s revenue was up .6% on a year-over-year basis. equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer declared that its board has authorized a stock repurchase program on Monday, December 18th that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

A number of equities research analysts have recently weighed in on PFE shares. Morningstar set a $38.00 target price on Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, January 30th. UBS set a $42.00 price objective on Pfizer and gave the company a “buy” rating in a report on Wednesday, January 31st. Nord/LB reiterated a “neutral” rating on shares of Pfizer in a report on Wednesday, December 27th. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price objective for the company in a report on Wednesday, January 24th. Finally, Sanford C. Bernstein set a $43.00 price objective on Pfizer and gave the company a “buy” rating in a report on Tuesday, January 30th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $39.40.

In other news, Director W Don Cornwell sold 1,758 shares of the company’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $36.79, for a total transaction of $64,676.82. Following the completion of the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at $36,790. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kirsten Lund-Jurgensen sold 9,510 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $37.19, for a total value of $353,676.90. Following the transaction, the insider now directly owns 36,959 shares of the company’s stock, valued at $1,374,505.21. The disclosure for this sale can be found here. Insiders have sold 248,037 shares of company stock valued at $9,064,785 over the last ninety days. 0.06% of the stock is owned by insiders.

WARNING: This report was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.watchlistnews.com/wealth-enhancement-advisory-services-llc-acquires-shares-of-57860-pfizer-inc-pfe/1956018.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.